Search hospitals > New York > Commack
MSK Commack
Claim this profileCommack, New York 11725
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Skin Cancer
Conducts research for Colorectal Cancer
Conducts research for Cancer
Conducts research for Plasma Cell Neoplasm
5 reported clinical trials
0 medical researchers
Summary
MSK Commack is a medical facility located in Commack, New York. This center is recognized for care of Non-Small Cell Lung Cancer, Skin Cancer, Colorectal Cancer, Cancer, Plasma Cell Neoplasm and other specialties. MSK Commack is involved with conducting 5 clinical trials across 29 conditions. There are 0 research doctors associated with this hospital, such as .Area of expertise
1Non-Small Cell Lung Cancer
Stage IV
Stage III
PD-L1 positive
2Skin Cancer
Stage IV
PD-L1 positive
Stage III
Top PIs
Clinical Trials running at MSK Commack
Multiple Myeloma
Lymphoma
Colorectal Cancer
Brain Tumor
Plasma Cell Neoplasm
Anaplastic Large Cell Lymphoma
Hodgkin's Lymphoma
Cutaneous T-Cell Lymphoma
Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma
Elranatamab Combinations
for Multiple Myeloma
The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of elranatamab in combination with the anti-CD38 monoclonal antibody daratumumab. People with multiple myeloma who have received previous treatment including lenalidomide will be enrolled in the study. Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab. People participating in Part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will evaluate the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab. Part 3 will assess the effect of increased measures to protect against infection in people treated with either elranatamab alone or together with daratumumab. All people participating in the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study.
Recruiting2 awards Phase 36 criteria
Elranatamab + Iberdomide
for Multiple Myeloma
The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will look at the correct amount of this combination that can be given to patients with relapsed or refractory multiple myeloma. Myeloma is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Refractory means a disease or condition that does not respond to treatment. Relapsed means the return of a disease after a period of improvement. All study medicines are given in cycles that last 28 days. Everyone taking part in this study will receive elranatamab as a shot under the skin. Iberdomide will be taken by mouth once a day for 21 days over a 28-day cycle. Participants will receive study medicine until: * their disease progresses or, * they experience unacceptable side effects or, * they choose to no longer take part in the study. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and can be used for multiple myeloma treatment.
Recruiting1 award Phase 1
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at MSK Commack?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.